Mirum Pharmaceuticals, Inc. MIRM Business Segments — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeBenefitsAndShareBasedCompensation.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s business segments — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s business segments — stock-based comp?
- Mirum Pharmaceuticals, Inc. (MIRM) reported business segments — stock-based comp of $57.13M in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s business segments — stock-based comp changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s business segments — stock-based comp increased by 269.2% year-over-year, from $15.47M to $57.13M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s business segments — stock-based comp?
- Over 3 years (2022 to 2025), Mirum Pharmaceuticals, Inc.'s business segments — stock-based comp has grown at a 37.5% compound annual growth rate (CAGR), from $27.01M to $70.25M.
- What does business segments — stock-based comp mean?
- Measures the non-cash expense recognized for equity-based awards granted to employees and executives. This metric is essential for understanding the total cost of human capital and the potential dilution impact on existing shareholders.